ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
방사성 리간드 요법 시장 규모는 최근 급성장하고 있습니다. 2025년 66억 3,000만 달러에서 2026년에는 73억 2,000만 달러에 이르고, CAGR 10.4%의 성장이 전망되고 있습니다. 지금까지의 성장 요인으로는 방사성 리간드 공급의 제한, 기존 암 치료에 대한 의존도, 표적 치료의 이점에 대한 인식 증가, 병원에서의 핵의학 기술 채택 확대, 초기 단계의 RLT 약물에 대한 규제 당국의 승인 등을 꼽을 수 있습니다.
방사성 리간드 요법 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 107억 2,000만 달러에 이르고, CAGR은 10.0%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 신규 알파 및 베타선 방출체 개발의 진전, 복합 방출 요법의 확대, 정밀 종양학과의 통합, 신경계 및 심혈관계 영역의 임상시험 증가, 재택치료 및 외래 RLT 서비스에 대한 투자 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 종양학 분야에서 표적 방사성 리간드 치료의 도입 확대, 알파-베타 방출체 기반 치료법의 확대, 방사성 리간드 치료와 개인 맞춤형 의료 접근법의 통합, 병원 및 연구기관 기반 RLT 프로그램의 성장, 부작용 최소화 및 환자 결과 개선의 중요성 증가 등이 있습니다. 부작용 최소화 및 환자 결과 개선의 중요성이 높아지고 있습니다.
암 발생률의 급격한 증가는 향후 방사성 리간드 치료 시장을 견인할 것으로 예측됩니다. 암은 조절할 수 없는 비정상적인 세포의 증식이 주변 조직으로 침범하여 전이되는 질환입니다. 그 증가는 DNA 손상, 세포 기능 장애, 이상 증식을 유발하는 환경독소에 장기간 노출된 경우와 관련이 있습니다. 방사성 리간드 치료는 수용체 결합 리간드를 통해 방사선을 유도하고 종양을 정밀하게 조사하여 암을 억제합니다. 건강한 조직을 보존하면서 세포 내부에서 사멸시킵니다. 예를 들어, 2025년 10월 기준 영국 공공의료기관인 국민보건서비스(NHS)는 2023년 35만 4,820건(하루 972건)의 신규 확진자를 기록해 2022년 대비 8,605건 증가하였습니다. 이처럼 암 발생률 증가는 방사성 리간드 치료 시장의 성장을 견인하고 있습니다.
방사성 리간드 치료제 시장의 주요 기업들은 정밀 암 치료제의 제조 및 공급에 있어 생산성, 품질, 안전성을 최적화하기 위해 전문 시설 등의 정비를 추진하고 있습니다. 방사성 리간드 치료 시설은 암 치료에 특화된 방사성 약제 관리 거점으로서 최첨단 영상진단 장비, 차폐시설, 전문 인력, 엄격한 안전대책을 갖추고 있습니다. 예를 들어, 2024년 1월 스위스 제약회사 노바티스(Novartis AG)는 FDA의 상업적 승인을 받은 후 인디애나주에 위치한 대규모 방사성 리간드 요법(RLT) 공장의 자동화를 실현했습니다. 70,000평방피트 규모의 이 시설은 노바티스의 최대 규모이자 가장 진보된 RLT 시설로, 완전 자동화를 통한 신속한 대량 생산이 가능해 미국 및 캐나다 환자들에게 더 많은 의약품을 공급할 수 있게 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Radioligand therapy (RLT) is an advanced targeted cancer treatment that combines a radioactive isotope with a ligand engineered to bind specifically to cancer cell receptors. Once administered, it locates tumor cells and delivers radiation directly to them, minimizing harm to healthy tissues. This targeted strategy helps reduce side effects and improve outcomes, especially in cancers resistant to conventional therapies.
The main types of radioligands in radioligand therapy include alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, typically just a few cell layers, making them highly effective for precise cell destruction. These radioligands target specific molecular markers such as hormone receptors, growth factor receptors, and tumor antigens, and can be administered via intravenous (IV), intramuscular (IM), subcutaneous, or oral routes. Radioligand therapy is applied in oncological, cardiovascular, neurological, and infectious disease treatments, and is utilized by hospitals, diagnostic laboratories, research institutions, and home care settings.
Tariffs have impacted the radioligand therapy market by increasing costs of imported radioactive isotopes, ligands, and specialized delivery equipment. Segments like alpha and beta emitter therapies are most affected, particularly in regions like North America and Europe, where imports dominate supply chains. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local production, investment in domestic radiopharmaceutical facilities, and innovation in cost-efficient RLT solutions.
The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including radioligand therapy industry global market size, regional shares, competitors with a radioligand therapy market share, detailed radioligand therapy market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.
The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.
The upsurge in cancer incidence is anticipated to boost the radioligand therapy market ahead. Cancer involves runaway abnormal cell proliferation that infiltrates nearby areas and metastasizes. Its rise links to prolonged environmental toxin exposure harming DNA, impairing cells, and spurring rogue growth. Radioligand therapy combats cancer by channeling radiation via receptor-binding ligands to zap tumors precisely, sparing healthy tissue for internal cell kill. For example, in October 2025, the National Health Service (NHS), a UK public health body, recorded 354,820 new cases in 2023-972 daily, up 8,605 from 2022. Thus, the climbing cancer incidence is fueling the radioligand therapy market.
Prominent companies in the radioligand therapy market are advancing setups like specialized radioligand therapy facilities to optimize output, quality, and safety in crafting and supplying pinpoint cancer drugs. Radioligand therapy facilities are dedicated hubs managing radioactive agents for focused cancer care, equipped with cutting-edge imaging, shielding, expert staff, and rigorous safeguards. For instance, in January 2024, Novartis AG, a Switzerland pharma leader, automated its massive Indiana radioligand therapy (RLT) plant post-FDA commercial nod. Spanning 70,000 square feet, it's Novartis's biggest, most sophisticated RLT site for swift, high-volume runs with full automation, ramping supply for US and Canada patients.
In December 2023, Eli Lilly and Company, a US pharma giant, snapped up POINT Biopharma Global Inc. for $1.4 billion. This bolsters Eli Lilly's oncology range with top-tier radioligand tech for sharper cancer precision meds. POINT Biopharma Global Inc. is a US firm honing radioligand cancer therapies.
Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.
North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Radioligand Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increasing Adoption Of Targeted Radioligand Therapy For Oncology
4.2.2 Expansion Of Alpha And Beta Emitter-Based Therapies
4.2.3 Integration Of Radioligand Therapy With Personalized Medicine Approaches
4.2.4 Growth In Hospital And Research Institution-Based RLT Programs
4.2.5 Rising Focus On Minimizing Side Effects And Enhancing Patient Outcomes
5. Radioligand Therapy Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Diagnostic Laboratories
5.3 Research Institutions
5.4 Home Care Settings
5.5 Specialty Cancer Centers
6. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Radioligand Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Radioligand Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Radioligand Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Radioligand Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Radioligand Therapy Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Radioligand Therapy Market Segmentation
9.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Radioligand Therapy Market
12.1. China Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Radioligand Therapy Market
13.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Radioligand Therapy Market
14.1. Japan Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Radioligand Therapy Market
15.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Radioligand Therapy Market
16.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Radioligand Therapy Market
17.1. South Korea Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Radioligand Therapy Market
18.1. Taiwan Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Radioligand Therapy Market
19.1. South East Asia Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Radioligand Therapy Market
20.1. Western Europe Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Radioligand Therapy Market
21.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Radioligand Therapy Market
22.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Radioligand Therapy Market
23.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Radioligand Therapy Market
24.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Radioligand Therapy Market
25.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Radioligand Therapy Market
26.1. Eastern Europe Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Radioligand Therapy Market
27.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Radioligand Therapy Market
28.1. North America Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Radioligand Therapy Market
29.1. USA Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Radioligand Therapy Market
30.1. Canada Radioligand Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Radioligand Therapy Market
31.1. South America Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Radioligand Therapy Market
32.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Radioligand Therapy Market
33.1. Middle East Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Radioligand Therapy Market
34.1. Africa Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Radioligand Therapy Market Regulatory and Investment Landscape
36. Radioligand Therapy Market Competitive Landscape And Company Profiles
36.1. Radioligand Therapy Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Radioligand Therapy Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Radioligand Therapy Market Company Profiles
36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Curium LLC Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Telix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
37. Radioligand Therapy Market Other Major And Innovative Companies
